Share on LinkedInShare on LinkedIn

ARTICLE · 09 APRIL 2015

N.D. Cal Interprets The Biological Price Competition Act

On March 19, the Northern District of California became the first court to interpret two key provisions of the Biological Price Competition Act...

United StatesIntellectual Property

Amgen Inc., et al. v. Sandoz Inc., et al., No. 14-cv-04741RS

On March 19, the Northern District of California became the first court to interpret two key provisions of the Biological Price Competition Act: whether biosimilar applicants must disclose their applications to patentees and how far in advance they must provide notice of their intent to enter the market.

The BPCIA, which was enacted as part of the Affordable Care Act, provides an abbreviated FDA licensing application pathway for producers of "biosimilars," biologic products that have been shown to be substantially similar to a product that has already been on the market for at least twelve years (so-called "reference products").  Pursuant to the BPCIA, the biosimilar's manufacturer may obtain FDA approval to sell its product by relying on safety, purity, and potency data the reference product's manufacturer (or "sponsor") provided to the FDA when it sought approval for the reference product.  This

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from